摘要
目的研究盐酸溴己新片与噻托溴铵联合用于慢性阻塞性肺疾病(以下简称慢阻肺)稳定期治疗的疗效及对患者血清髓过氧化物酶(myeloperoxidase,MPO)、白介素-4(interleukin-4,IL-4)水平的影响。方法摘选98例2020年3月—2021年3月南阳市第一人民医院收治的慢阻肺稳定期患者,以治疗药物的不同进行分组,给予盐酸溴己新片用药的患者为对照组(n=49),以盐酸溴己新片与噻托溴铵联合用药的患者为观察组(n=49),对比组间治疗结果。结果治疗后,观察组总有效率(97.95%)高于对照组(85.71%),差异有统计学意义(P<0.05,χ^(2)=4.900);观察组血清MPO、IL-4指标水平均明显低于对照组,P<0.05(t=3.866,t=12.060);而观察组不良反应发生率(6.12%)与对照组(2.04%)对比则显示无明显差异,P>0.05(χ^(2)=1.042)。结论盐酸溴己新片与噻托溴铵双药联合治疗慢阻肺稳定期疗效更胜于盐酸溴己新片单药治疗,有效降低患者的血清MPO与IL-4指标水平,且未明显增加药物不良反应,疗效与安全均值得信赖,建议临床积极推广。
Objective To investigate the efficacy of bromohexanil hydrochloride combined with tiotropium bromide in the stable treatment of chronic obstructive pulmonary disease(COPD)and the effects on the levels of myeloperoxidase(MPO)and interleukin-4(IL-4)in serum of patients.Methods Selected 98 cases from March 2020 to March 2021 in Nanyang the first people’s hospital of patients with copd stabilization in treatments of different grouping,giving hydrochloride bromine has new medication of patients as control group(n=49),hydrochloric acid bromide in the film and thiamethoxam bromide combination of patients as observation group(n=49),the results of the comparison between groups.Results After treatment,the total effective rate of the observation group(97.95%)was higher than that of the control group(85.71%),the difference was statistically significant(P<0.05,χ^(2)=4.900).The levels of serum MPO and IL-4 in observation group were significantly lower than those in control group,P<0.05(T=3.866,T=12.060);There was no significant difference in the incidence of adverse reactions between the observation group(6.12%)and the control group(2.04%),P>0.05(χ^(2)=1.042).Conclusion The efficacy of bromopropyl hydrochloride alone is better than that of bromopropyl hydrochloride combined alone in the treatment of COPD at stable stage,and it can effectively reduce the levels of serum MPO and IL-4 indexes of patients,without significantly increasing adverse drug reactions.The efficacy and safety are both reliable,and it is recommended to be promoted actively in clinical practice.
作者
陈璐
侯太辉
李静
CHEN Lu;HOU Tai-hui;LI Jing(Department of Respiratory Critical Care medicine,Nanyang First People's Hospital,Nanyang,Henan 473000,China)
出处
《医药论坛杂志》
2021年第21期57-60,共4页
Journal of Medical Forum
